Personalis, Inc. income statement
In fiscal 2025, Personalis, Inc. reported revenue of $69.6m, down 17.7% on the year before, operating income of −$88.1m (a -126.4% margin) and net income of −$81.3m, or −$0.91 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 38 | 65 | 79 | 85 | 65 | 73 | 85 | 70 | 70 |
| Cost of revenue | 12 | 26 | 43 | 59 | 54 | 52 | 55 | 58 | 54 | 61 |
| Gross profit | −2 | 12 | 22 | 20 | 32 | 13 | 18 | 27 | 16 | 9 |
| Research and development | 10 | 14 | 22 | 29 | 49 | 65 | 65 | 49 | 50 | 56 |
| Selling, general and administrative | 10 | 11 | 22 | 34 | 48 | 64 | 50 | 46 | 54 | 67 |
| Operating income | −22 | −14 | −22 | −42 | −65 | −116 | −110 | −68 | −88 | −114 |
| Interest expense | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −24 | −20 | −25 | −41 | −65 | −113 | −108 | −81 | −81 | −107 |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −24 | −20 | −25 | −41 | −65 | −113 | −108 | −81 | −81 | −107 |
| Diluted EPS | −$3.89 | −$3.25 | −$0.69 | −$1.20 | −$1.49 | −$2.48 | −$2.25 | −$1.37 | −$0.91 | −$1.10 |
| Diluted shares (average) | 6m | 6m | 36m | 34m | 44m | 46m | 48m | 59m | 89m | 98m |
| EBITDA | −21 | −11 | −18 | −36 | −59 | −107 | −99 | −57 | −78 | −105 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26 | 17 | 21 | 17 | 14 | 17 | 15 | 22 |
| Cost of revenue | 17 | 12 | 13 | 12 | 13 | 15 | 15 | 18 |
| Gross profit | 9 | 5 | 7 | 5 | 2 | 2 | 0 | 5 |
| Research and development | 12 | 11 | 13 | 12 | 12 | 13 | 15 | 16 |
| Selling, general and administrative | 11 | 11 | 12 | 14 | 13 | 14 | 18 | 22 |
| Operating income | −14 | −18 | −18 | −22 | −23 | −25 | −32 | −34 |
| Interest expense | 0 | −0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −39 | −16 | −16 | −20 | −22 | −24 | −30 | −32 |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −39 | −16 | −16 | −20 | −22 | −24 | −30 | −32 |
| Diluted EPS | −$0.64 | −$0.18 | −$0.18 | −$0.23 | −$0.24 | −$0.26 | −$0.29 | −$0.30 |
| EBITDA | −12 | −16 | −15 | −19 | −21 | −23 | −30 | −31 |
Compare with peers
- Exagen Inc. income statement
- Burning Rock Biotech Ltd income statement
- Codexis, Inc. income statement
- 908 Devices Inc. income statement
- Precipio, Inc. income statement
Head to head: PSNL vs XGNBNR vs PSNLCDXS vs PSNLMASS vs PSNL
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies